Case report: Osteomalacia due to bisphosphonate treatment in a patient on hemodialysis

Abstract

Background No publications have reported on osteomalacia in patients receiving intermittent cyclical therapy with etidronate (a bisphosphonate) and undergoing long-term hemodialysis (HD). Case presentation We report on a 46-year-old Japanese man admitted to our hospital for further examination of left forearm pain. Maintenance HD was started at age 24\u2009years, and the man had been on HD since then. At age 38\u2009years, surgical parathyroidectomy was performed for secondary hyperparathyroidism; iliac crest bone biopsy performed at the same time showed osteitis fibrosa. The active vitamin D 3 preparation calcitriol was started, and intermittent cyclical etidronate therapy was introduced 2\u2009years later for osteoporosis. At age 45\u2009years, the patient stopped taking calcitriol because of hypercalcemia but continued with etidronate. At age 46\u2009years, a pseudofracture with a Looser zone occurred in the left ulna, and left femur bone biopsy revealed osteomalacia. Etidronate was discontinued, and calcitriol was restarted; open reduction and internal fixation with an angular stability plate were performed. Union of the bone was achieved 10\u2009months after the operation. At age 49\u2009years, a lumber bone biopsy confirmed improved bone morphometry. Conclusions We believe that intermittent cyclical etidronate therapy without administration of active vitamin D 3 during long-term HD might have induced osteomalacia, resulting in the ulna insufficiency fracture. Therefore, we propose that administration of active vitamin D 3 is essential to prevent osteomalacia in patients on long-term HD who are receiving bisphosphonates and have potential vitamin D 3 deficiency.